{"disease":{"id":"psma","name":"psma"},"drugs":{"marketed":[{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"lutetium-lu-177-vipivotide-tetraxetan","indication_name":"PSMA-positive mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN","company_name":"","drug_phase":"marketed","molecular_target":"PSMA","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Lutetium Lu 177 vipivotide tetraxetan binds to PSMA on prostate cancer cells, delivering radiation that causes DNA damage and cell death."},{"drug_id":"pluvicto","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pluvicto","company_name":"VA Office of Research and Development","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"","quality_score":11,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06320223","title":"PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT07089550","title":"PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)","phase":"","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04775602","title":"Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT06690970","title":"Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Tianjin Medical University","has_results":false},{"nct_id":"NCT04987086","title":"68Ga-PSMA PET in the Renal Cell Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT04967001","title":"68Ga-PSMA PET in the Prostate Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT03465579","title":"Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.","phase":"NA","overall_status":"TERMINATED","enrollment_count":261,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT05822726","title":"The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06923657","title":"PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT06217822","title":"First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06850545","title":"Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT03454750","title":"Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT07226986","title":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":123,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06901492","title":"The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT06600802","title":"Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Centre Jean Perrin","has_results":false},{"nct_id":"NCT04429451","title":"PSMA-specific CAR-T Cell Therapy","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT06419348","title":"99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT06387381","title":"68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT07485257","title":"Molecular Profiling of MRI-PSMA PET Discordance in Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT07169825","title":"Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function","phase":"NA","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05596851","title":"Radio-guided Surgery With DROP-IN Beta Probe for 68Ga-PSMA, in High-risk Prostate Cancer Patients Eligible for Robotic-assisted Radical Prostatectomy.","phase":"","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT06809426","title":"Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Affiliated Hospital of Jiangnan University","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}